newsletter/ hy report, page-6

I haven't added it all up but I would not be expecting a profit this year (to 31/12/2013). However, it has been getting closer and closer these last few years and now with the extra MRI scan centres in November 2013 and FDA approval of Hepafat on 20 December 2013, we are very likely to be showing a profit soon. That profit should increase rapidly over the next few years.

There is little doubt that RHT is way undervalued. Most of the stocks it seems to be lumped in with (mainly by day traders, who are ruling the price just now) are no where near profit and many are not even earning any revenue. In some ways its a pity RHT took off so quickly and attracted all the day traders who do not understand the basic fundamentals of what revenue and profit mean. They are prepared to sell at considerable loss regardless of the long term value.

All this company needs is for one of the small company funds to do an professional assessment of it.